✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Unjha Formulations Ltd.

UNJHAFOR

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹12 Cr.
P/E
11.78

Unjha Formulations Ltd.

  • Unjha Formulations
  • Beryl Drugs
  • Parmax Pharma

FAQs on Unjha Formulations Ltd. Shareprice

Unjha Formulations has given better returns compared to its competitors.
Unjha Formulations has grown at ~34.2% over the last 3yrs while peers have grown at a median rate of -2.8%

Unjha Formulations is not expensive.
Latest PE of Unjha Formulations is 11.78, while 3 year average PE is 27.23.
Also latest EV/EBITDA of Unjha Formulations is 8.34 while 3yr average is 25.59.

View FAQ's On Business

Growth Table

  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Balance Sheet

  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Cash Flow

  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Quarterly Results

  • Unjha Formulations Ltd.
  • Beryl Drugs
  • Parmax Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Unjha Formulations Ltd. Financials

Balance sheet of Unjha Formulations is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Unjha Formulations is decreasing.
Latest net debt of Unjha Formulations is -₹1.6 Crs as of Sep-25.
This is less than Mar-25 when it was -₹1.29 Crs.

Yes, profit is increasing.
The profit of Unjha Formulations is ₹1.02 Crs for TTM, ₹0.41 Crs for Mar 2025 and ₹0.28 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Unjha Formulations latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech